New DXR Option Grant Highlights Director Incentive Alignment
Rhea-AI Filing Summary
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
The award is contingent upon SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Goudie Joy S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 2,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (right to buy) — 2,500 shares (Direct)
Footnotes (2)
- F1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
- F2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How many stock options did DXR grant to director Joy S. Goudie?
The Form 4 shows a grant of 2,500 stock options with a strike price of $9.29 per share.
What is the vesting schedule for Joy Goudie’s 2,500 DXR options?
The options vest in three installments: 833 on 6/24/2025, 883 on 6/24/2026, and 834 on 6/24/2027.
Are the granted options subject to any conditions?
Yes. The grant is contingent upon SEC approval to amend Daxor’s 2020 Incentive Compensation Plan.